Premium
METHOTREXATE * IN PSORIASIS
Author(s) -
SCHEWACHMILLET M.,
ZIPRKOWSKI L.
Publication year - 1968
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1968.tb12344.x
Subject(s) - psoriasis , methotrexate , dermatology , medicine , dermatologic agents , chemistry , antibiotics , biochemistry
SUMMARY. Seventeen patients with widespread psoriasis were treated with parenteral methotrexate over a period of 2–88 weeks. The injections were given every 1–4 weeks, in a dose of 12·5–37·5 mg. The best results were obtained with a dose of 25 mg. of methotrexate once weekly. The improvement can be maintained only by continued treatment. One of our patients suffered from psoriasis and systemic lupus erythematosus; both conditions were improved. Apart from nausea and leukopenia no complications or side effects were noted. However, methotrexate is a potentially dangerous agent which should be administered only under careful hospital supervision. In the light of our experience we feel that methotrexate in the treatment of psoriasis deserves further investigation.